Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Emma Watz et al.|Clinical Cancer Research|2018Cited by 195
Supplementary Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Unknown|2023Cited by 0
Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Unknown|2023Cited by 0
Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Unknown|2023Cited by 0
Supplementary Data from Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AMLAndreas T. Björklund, Karl‐Johan Malmberg, Mattias Carlsten et al.|Unknown|2023Cited by 0